Cargando…

LncRNA HOXA11-AS promotes glioma malignant phenotypes and reduces its sensitivity to ROS via Tpl2-MEK1/2-ERK1/2 pathway

Our previous studies showed that dysregulation of the long noncoding RNA (lncRNA) HOXA11-AS plays an important role in the development of glioma. However, the molecular mechanism of HOXA11-AS in glioma remains largely unknown. In this study, we explore the molecular mechanisms underlying abnormal ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Cheng, Zhang, Xiaoyang, Peng, Dazhao, Zhang, Xu, Guo, Haizhen, Lu, Yalin, Luo, Lin, Wang, Bo, Li, Zesheng, He, Yingjie, Du, Xuezhi, Zhang, Shu, Liang, Hao, Li, Shenghui, Wang, Sheng, Han, Lei, Zhang, Jianning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646708/ https://www.ncbi.nlm.nih.gov/pubmed/36351895 http://dx.doi.org/10.1038/s41419-022-05393-5

Ejemplares similares

IKBKE-driven TPL2 and MEK1 phosphorylations sustain constitutive ERK1/2 activation in tumor cells
por: Göktuna, Serkan Ismail
Publicado: (2022)

Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas
por: Wei, Cheng, et al.
Publicado: (2022)

Corrigendum: Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas
por: Wei, Cheng, et al.
Publicado: (2022)

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia
por: Chorzalska, Anna, et al.
Publicado: (2018)

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Foot-and-Mouth Disease Virus Structural Protein VP1 Destroys the Stability of the TPL2 Trimer by Degradation of TPL2 To Evade Host Antiviral Immunity
por: Zhang, Keshan, et al.
Publicado: (2021)

Tpl2 contributes to IL-1β-induced IL-8 expression via ERK1/2 activation in canine dermal fibroblasts
por: Naruke, Atsuto, et al.
Publicado: (2021)

TPL-2 Inhibits IFN-β Expression via an ERK1/2-TCF-FOS Axis in TLR4-Stimulated Macrophages
por: Blair, Louise, et al.
Publicado: (2022)

Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?
por: Rousseau, Simon, et al.
Publicado: (2016)

TPL2 kinase expression is regulated by the p38γ/p38δ-dependent association of aconitase-1 with TPL2 mRNA
por: Escós, Alejandra, et al.
Publicado: (2022)

Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor–activated macrophages
por: López-Pelaéz, Marta, et al.
Publicado: (2012)

The Protein Kinase TPL2 Is Essential for ERK1/ERK2 Activation and Cytokine Gene Expression in Airway Epithelial Cells Exposed to Pathogen-Associated Molecular Patterns (PAMPs)
por: Martel, Guy, et al.
Publicado: (2013)

Tumor Progression Locus 2 (Tpl2) Kinase as a Novel Therapeutic Target for Cancer: Double-Sided Effects of Tpl2 on Cancer
por: Lee, Hye Won, et al.
Publicado: (2015)

SlTPL1 Silencing Induces Facultative Parthenocarpy in Tomato
por: He, Mi, et al.
Publicado: (2021)

MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways
por: Zhang, Zeng-Qiao, et al.
Publicado: (2021)

TRAF7-targeted HOXA5 acts as a tumor suppressor in prostate cancer progression and stemness via transcriptionally activating SPRY2 and regulating MEK/ERK signaling
por: Ye, Jianfeng, et al.
Publicado: (2023)

TPL2/COT/MAP3K8 (TPL2) Activation Promotes Androgen Depletion-Independent (ADI) Prostate Cancer Growth
por: Jeong, Joseph H., et al.
Publicado: (2011)

UBTF facilitates melanoma progression via modulating MEK1/2-ERK1/2 signalling pathways by promoting GIT1 transcription
por: Zhang, Jian, et al.
Publicado: (2021)

ARID1B/SUB1‐activated lncRNA HOXA‐AS2 drives the malignant behaviour of hepatoblastoma through regulation of HOXA3
por: Liu, Gongbao, et al.
Publicado: (2021)

Deregulation of Hepatic Mek1/2–Erk1/2 Signaling Module in Iron Overload Conditions
por: Tangudu, Naveen Kumar, et al.
Publicado: (2019)

Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma
por: Hu, Huanrong, et al.
Publicado: (2019)

Expression of the Tpl2/Cot oncogene in human T-cell neoplasias
por: Christoforidou, Anna V, et al.
Publicado: (2004)

TPL2 mediates IL-17R signaling in neuroinflammation
por: Xiao, Yichuan, et al.
Publicado: (2015)

Praja2 suppresses the growth of gastric cancer by ubiquitylation of KSR1 and inhibiting MEK-ERK signal pathways
por: Zhao, Zhiwei, et al.
Publicado: (2021)

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
por: Gruosso, Tina, et al.
Publicado: (2015)

Cardiac Hormones Target the Ras-MEK 1/2-ERK 1/2 Kinase Cancer Signaling Pathways
por: Vesely, David L.
Publicado: (2011)

The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
por: Guégan, Jean-Philippe, et al.
Publicado: (2012)

PADI2‐Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1‐Mediated SOX2 mRNA Stability in Endometrial Cancer
por: Xue, Teng, et al.
Publicado: (2021)

Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway
por: Ma, Xiaofeng, et al.
Publicado: (2017)

The Effect of Arrestin Conformation on the Recruitment of c-Raf1, MEK1, and ERK1/2 Activation
por: Coffa, Sergio, et al.
Publicado: (2011)

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Effects of Camphorquinone on Cytotoxicity, Cell Cycle Regulation and Prostaglandin E(2) Production of Dental Pulp Cells: Role of ROS, ATM/Chk2, MEK/ERK and Hemeoxygenase-1
por: Chang, Mei-Chi, et al.
Publicado: (2015)

Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma
por: ZHANG, ZHI, et al.
Publicado: (2016)

TPL2-NPM-p53 pathway monitors nucleolar stress
por: Eliopoulos, Aristides G., et al.
Publicado: (2015)

TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus
por: Kannan, Yashaswini, et al.
Publicado: (2017)

Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor Cells
por: Xu, Jing, et al.
Publicado: (2019)

Study of Promoter Methylation Patterns of HOXA2, HOXA5, and HOXA6 and Its Clinicopathological Characteristics in Colorectal Cancer
por: Li, Daojiang, et al.
Publicado: (2019)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
por: Beuret, Laurent, et al.
Publicado: (2021)

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway
por: Cai, Jun, et al.
Publicado: (2010)

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway
por: Cai, Jun, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n2gjdeud6glj7slgkis9govkqi